BioSpace News Archive

According to Emergen Research, the global rehabilitation robotics market size was USD 2.77 billion in 2020 and is expected to reach USD 11.38 billion in 2028 and register a revenue CAGR of 20.5% during the forecast period, 2021-2028.

Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on developing its excimer laser system to treat vascular diseases, today announced the closing of an underwritten public offering of units and pre-funded units for aggregate gross proceeds of approximately $12.1 million.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

BioLife Sciences is pleased to announce the launching of a new life sciences division, aimed at honing in on disruptive technology and solutions with a focus on antimicrobial supported pomology, olericulture, floriculture and general plant sciences.

STERIS plc announced financial results for its fiscal 2022 third quarter ended December 31, 2021.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) (“Karyopharm,” the “Company,” “we” and “our”), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Cyteir Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 2 expansion cohort study of CYT-0851 monotherapy that is part of the Phase 1/2 trial. CYT-0851 is being evaluated for the treatment of hematologic malignancies and solid tumors.

Catalyst Clinical Research and Ledger Run will partner to create streamlined clinical trial business processes to enhance and accelerate global studies.

Palisade Bio, Inc. announced today that data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN) has been selected for a presentation in The Next Big Thing session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2022 Annual Meeting.